3-dimensional printing (3DP) of medicines is becoming an increasingly popular trend, especially since the first 3D printed medicine (Spritam®) was approved by the FDA in August 2015.
Researchers from University College London – School of Pharmacy and FabRx Ltd. have recently published a paper in International Journal of Pharmaceutics in which they show, for the first time, the fabrication of oral tablets by stereolithography.
Stereolithography (SLA) is a type of 3DP technology, based on the solidification of a liquid resin by photopolymerization. A laser is focused on to a specific depth in a vat of resin, causing localized polymerization (and so solidification). Solidification is repeated in a layer by layer manner until a solid, 3D object is produced. SLA is superior to other 3DP techniques in terms of resolution.
In a previous study, approximately 50% of the model drug 4-aminosalicylic acid (4-ASA) was degraded during 3D printing. Read more